Expanding the Scope of Precision Care for Patients With HR-Positive Breast Cancers: Things You Should Know
Learn from expert faculty as they discuss application of recent clinical evidence to develop personalized treatment plans for HR-positive/HER2-negative early and advanced breast cancer the use of current and emerging oral targeted therapies and strategies to promote adherence with a downloadable slideset from a satellite symposium an on-demand webcast and expert commentary.
Associate Attending Breast Medicine Service and Early Drug Development Service Section Head, Endocrine Therapy Research Program Clinical Director, Early Drug Development Service Department of Medicine Associate Professor of Medicine Weill Cornell Medical College New York, New York
Erica Mayer, MD, MPH
Director of Breast Cancer Clinical Research Dana-Farber Cancer Institute Associate Professor of Medicine Harvard Medical School Boston, Massachusetts
Laura M. Spring, MD
Breast Medical Oncologist Mass General Cancer Center Harvard Medical School Boston, Massachusetts